Skip Navigation

European Journal of Heart Failure 2000 2(1):107-112; doi:10.1016/S1388-9842(00)00053-2
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Witte, K.
Right arrow Articles by Cleland, J. G.F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Witte, K.
Right arrow Articles by Cleland, J. G.F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2000 European Society of Cardiology

Update of ELITE-II, BEST, CHAMP, and IMPRESS clinical trials in heart failure

Klaus Witte*, Simon Thackray, Tumpa Banerjee, Andrew L. Clark and John G.F. Cleland

The University of Hull, Department of Cardiology, Academic Unit of Cardiology, Castle Hill Hospital Kingston upon Hull, HU16 5JQ, UK

* Corresponding author. Tel.: +44-1482-624087; fax: +44-1482-624085.


  Abstract

The ELITE-II, BEST and CHAMP Trials were reported for the first time at the American Heart Association in November 1999. These trials provide valuable new information to guide clinical practice in the management of heart failure and of myocardial infarction, although none mandate a major change from current clinical practice. The IMPRESS trial of the vasopeptidase inhibitor, omapatrilat, indicated a promising new treatment for the management of heart failure.

Received December 13, 1999; Revised December 17, 1999; Accepted December 17, 1999


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur J Heart FailHome page
C. H.M. van Jaarsveld, A. V. Ranchor, G. I.J.M. Kempen, J. C. Coyne, D. J. van Veldhuisen, and R. Sanderman
Epidemiology of heart failure in a community-based study of subjects aged >=57 years: Incidence and long-term survival
Eur J Heart Fail, January 1, 2006; 8(1): 23 - 30.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
S. D.R. Thackray, K. K.A. Witte, A. Khand, A. Dunn, A. L. Clark, and J. G.F. Cleland
Clinical trials update: highlights of the scientific sessions of the American Heart Association year 2000: Val HeFT, COPERNICUS, MERIT, CIBIS-II, BEST, AMIOVIRT, V-MAC, BREATHE, HEAT, MIRACL, FLORIDA, VIVA and the first human cardiac skeletal muscle myoblast transfer for heart failure
Eur J Heart Fail, January 1, 2001; 3(1): 117 - 124.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
K. Witte, S. Thackray, A. L. Clark, M. Cooklin, and J. G.F. Cleland
Clinical trials update: IMPROVEMENT-HF, COPERNICUS, MUSTIC, ASPECT-II, APRICOT and HEART
Eur J Heart Fail, December 1, 2000; 2(4): 455 - 460.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
J. Mcmurray
Beta-blockers, ventricular arrhythmias, and sudden death in heart failure: not as simple as it seems
Eur. Heart J., August 1, 2000; 21(15): 1214 - 1215.
[PDF]

Home page
 Eur J Heart FailHome page
S. Thackray, K. Witte, A. L. Clark, and J. G.F. Cleland
Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT
Eur J Heart Fail, June 1, 2000; 2(2): 209 - 212.
[Abstract] [Full Text] [PDF]

Home page
 DTBHome page
Heart failure drugs: whats new?
DTB, April 1, 2000; 38(4): 25 - 27.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Renin-Angiotensin-Aldosterone SystemHome page
R. Willenbrock, S. Philipp, V. Mitrovic, and R. Dietz
Neurohumoral blockade in CHF management
Journal of Renin-Angiotensin-Aldosterone System, March 1, 2000; 1(1_suppl): 24 - 30.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.